BBIO
BridgeBio Pharma, Inc.NASDAQHealthcare$73.15-1.75%ClosedMarket Cap: $14.18B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-6.95
P/S
28.24
EV/EBITDA
-26.25
DCF Value
$-127.65
FCF Yield
-3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.4%
Operating Margin
-113.3%
Net Margin
-145.3%
ROE
39.2%
ROA
-80.3%
ROIC
-108.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $154.2M | 90.0% | $-185.2M | $-197.2M | $-1.00 | — |
| FY 2025 | $502.1M | 94.4% | $-569.1M | $-729.3M | $-3.79 | — |
| Q3 2025 | $120.7M | 94.6% | $-145.2M | $-182.7M | $-0.96 | — |
| Q2 2025 | $110.6M | 96.7% | $-134.3M | $-181.9M | $-0.95 | — |
| Q1 2025 | $116.6M | 97.7% | $-104.4M | $-167.4M | $-0.88 | — |
| Q4 2024 | $5.9M | 64.6% | $-226.0M | $-265.1M | $-1.40 | — |
| FY 2024 | $221.9M | 98.3% | $-593.0M | $-535.8M | $-2.88 | — |
| Q3 2024 | $2.7M | 78.1% | $-191.8M | $-162.0M | $-0.86 | — |
| Q2 2024 | $2.2M | 72.4% | $-175.5M | $-73.5M | $-0.39 | — |
| Q1 2024 | $211.1M | 99.7% | $343.0K | $-35.2M | $-0.20 | — |
| Q4 2023 | $1.7M | 65.7% | $-177.4M | $-168.1M | $-0.96 | — |
| FY 2023 | $9.3M | 73.7% | $-607.4M | $-643.2M | $-3.95 | — |